178 related articles for article (PubMed ID: 25701378)
1. Celecoxib sensitizes gastric cancer to rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway.
Cao Y; Qu J; Li C; Yang D; Hou K; Zheng H; Liu Y; Qu X
Tumour Biol; 2015 Jul; 36(7):5607-15. PubMed ID: 25701378
[TBL] [Abstract][Full Text] [Related]
2. Reversal of P-glycoprotein-mediated multi-drug resistance by the E3 ubiquitin ligase Cbl-b in human gastric adenocarcinoma cells.
Zhang Y; Qu X; Hu X; Yang X; Hou K; Teng Y; Zhang J; Sada K; Liu Y
J Pathol; 2009 Jun; 218(2):248-55. PubMed ID: 19274672
[TBL] [Abstract][Full Text] [Related]
3. PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells.
Li D; Qu X; Hou K; Zhang Y; Dong Q; Teng Y; Zhang J; Liu Y
Anticancer Drugs; 2009 Jan; 20(1):59-64. PubMed ID: 19343001
[TBL] [Abstract][Full Text] [Related]
4. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
[TBL] [Abstract][Full Text] [Related]
5. Ubiquitin ligase Cbl-b represses IGF-I-induced epithelial mesenchymal transition via ZEB2 and microRNA-200c regulation in gastric cancer cells.
Li H; Xu L; Li C; Zhao L; Ma Y; Zheng H; Li Z; Zhang Y; Wang R; Liu Y; Qu X
Mol Cancer; 2014 Jun; 13():136. PubMed ID: 24885194
[TBL] [Abstract][Full Text] [Related]
6. Casitas B-lineage lymphoma mutants activate AKT to induce transformation in cooperation with class III receptor tyrosine kinases.
Polzer H; Janke H; Schmid D; Hiddemann W; Spiekermann K
Exp Hematol; 2013 Mar; 41(3):271-80.e4. PubMed ID: 23127761
[TBL] [Abstract][Full Text] [Related]
7. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Sun SY; Rosenberg LM; Wang X; Zhou Z; Yue P; Fu H; Khuri FR
Cancer Res; 2005 Aug; 65(16):7052-8. PubMed ID: 16103051
[TBL] [Abstract][Full Text] [Related]
8. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation.
Li Y; Qu X; Qu J; Zhang Y; Liu J; Teng Y; Hu X; Hou K; Liu Y
Cancer Lett; 2009 Nov; 284(2):208-15. PubMed ID: 19457607
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway.
Li J; Xue L; Hao H; Li R; Luo J
Tumour Biol; 2014 Jul; 35(7):6467-74. PubMed ID: 24682932
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
12. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
Meric-Bernstam F; Akcakanat A; Chen H; Do KA; Sangai T; Adkins F; Gonzalez-Angulo AM; Rashid A; Crosby K; Dong M; Phan AT; Wolff RA; Gupta S; Mills GB; Yao J
Clin Cancer Res; 2012 Mar; 18(6):1777-89. PubMed ID: 22422409
[TBL] [Abstract][Full Text] [Related]
14. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
[TBL] [Abstract][Full Text] [Related]
15. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
[TBL] [Abstract][Full Text] [Related]
16. A study on the mechanism of rapamycin mediating the sensitivity of pancreatic cancer cells to cisplatin through PI3K/AKT/mTOR signaling pathway.
Li B; Yang J; Lu Z; Liu B; Liu F
J BUON; 2019; 24(2):739-745. PubMed ID: 31128031
[TBL] [Abstract][Full Text] [Related]
17. Celecoxib regulates apoptosis and autophagy via the PI3K/Akt signaling pathway in SGC-7901 gastric cancer cells.
Liu M; Li CM; Chen ZF; Ji R; Guo QH; Li Q; Zhang HL; Zhou YN
Int J Mol Med; 2014 Jun; 33(6):1451-8. PubMed ID: 24676394
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells.
Lu R; Zhao G; Yang Y; Jiang Z; Cai J; Hu H
Technol Cancer Res Treat; 2019 Jan; 18():1533033819864311. PubMed ID: 31405336
[TBL] [Abstract][Full Text] [Related]
19. Anti-gastric cancer effects of celecoxib, a selective COX-2 inhibitor, through inhibition of Akt signaling.
Kim N; Kim CH; Ahn DW; Lee KS; Cho SJ; Park JH; Lee MK; Kim JS; Jung HC; Song IS
J Gastroenterol Hepatol; 2009 Mar; 24(3):480-7. PubMed ID: 18823436
[TBL] [Abstract][Full Text] [Related]
20. Cbl-b promotes chemotherapy-induced apoptosis in rat basophilic leukemia cells by suppressing PI3K/Akt activation and enhancing MEK/ERK activation.
Qu X; Li Y; Liu J; Xu L; Zhang Y; Hu X; Hou K; Liu Y
Mol Cell Biochem; 2010 Jul; 340(1-2):107-14. PubMed ID: 20177738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
